This Week in Biotech: A Trifecta of Disappointment Mars ASCO While Biogen Scores a Big Victory

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 7 June, 2014 by The TZ Newswire Staff

This Week in Biotech: A Trifecta of Disappointment Mars ASCO While Biogen Scores a Big Victory

Three disappointing studies highlight this past week’s ASCO data while Biogen Idec and two other biotechs deliver positive regulatory news to investors.

See also
- Next Article Selling Your European Stocks Before Everyone Else Sees This Chart?
- Previous Article Is General Electric Company Destined for Greatness?
Editorial Calender

June 2014

M T W T F S S

1

2 3 4 5 6 7 8

9 10 11 12 13 14 15

16 17 18 19 20 21 22

23 24 25 26 27 28 29

30

« May Jul »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar

The Traderszone Network

Editorial Archives

Published in TZ Latest News 7 June, 2014 by The TZ Newswire Staff

This Week in Biotech: A Trifecta of Disappointment Mars ASCO While Biogen Scores a Big Victory

See also

Editorial Calender

Recent Tags